

# CONTROL siRNA Technical Data Sheet (TDS)

For Research Use Only

NAME REFERENCE FINAL AMOUNT CHEMISTRY

siRNA NuMa control
siRNA duplex - human

1 siRNA negative control duplex is made of two complementary strands
Antisense strand

dTdT 3' overhang

Sense strand dTdT 3' overhang

**MODIFICATIONS 5' OR 3'** 

None

PURIFICATION QC STATUS
IEX-HPLC Passed

#### **DELIVERY CONDITION**

Shipped lyophilized

Additional reagent supplied: 1 ml RNase-free Water

#### **RECONSTITUTION**

To make up to 100 µM concentration, add 50.0 µl of recommended buffer.

To make up to 20 µM concentration, add 250.0 µI of recommended buffer.

To make up to 5 µM concentration, add 1.00 ml of recommended buffer.

#### STORAGE CONDITION

Store siRNAs (and RNA oligos in general) as a dry pellet at  $-20~^{\circ}$ C (or preferably -70  $^{\circ}$ C) in a non-frost free freezer until ready to use. Once resuspended in RNase-free buffer, store at  $-70~^{\circ}$ C and avoid contact with RNases. siRNA should be resuspended to a convenient stock concentration (e.g. 50  $\mu$ M), and stored in small aliquots to avoid multiple freeze thaw cycles. When stored under these conditions and using good RNase-free technique, they typically remain stable for 6 months or more. The solution can be freeze-thawed up to 5 times. For long-term storage, siRNA oligos should be kept dried.

#### **DESCRIPTION**

The Positive Control siRNAs are used to validate experimental results and to ensure that the method used is suitable to perform an RNAi assay. Positive control can also be used to normalize obtained results.

The Positive Control siRNAs consist of a duplex siRNA directed against a range of endogenous and reporter genes.

For more information, do not hesitate to contact us.

#### Disclaimers and trademarks:

RNA interference is licensed under European Patents 1144623, 1214945 and foreign equivalents from Alnylam Pharmaceuticals, Inc., Cambridge, USA and is provided only for use in academic and commercial research (excluding the evaluation or characterization of this product as the potential basis for a siRNA-based drug) and not for any other commercial purposes. Information about licenses for commercial use (including discovery and development of siRNA-based drugs) is available from Alnylam Pharmaceuticals, Inc., 300 Third Street, Cambridge, MA 02142, USA.

#### **TECHNICAL SUPPORT**

If you have any questions feel free to contact us

⊠ oligo@eurogentec.com

### **EUROPE**

Kaneka Eurogentec S.A. Liège Science Park Rue Bois Saint-Jean 5 - 4102 SERAING BELGIUM Tel: +32(0)4 372 74 00 - Fax: +32(0)4 264 07 88 E-mail info@eurogentec.com Web: www.eurogentec.com

RPM Liège T.V.A.-(BE)-0427.348.346

## **NORTH AMERICA**

EGT North America, Inc. 34801 Campus Drive - Fremont, CA 94555 Tel.: +1 (510) 896 -1350 \* Fax: +1 (510) 791-9572 E-mail: info@eurogentec.com Web: www.eurogentec.com